Wendy Taylor is focused on identifying market-based solutions to address diseases and conditions of poverty in the developing world. Currently, she is serving as Senior Adviser on Innovative Finance and Public Private Partnerships at the US Agency for International Development and helping launch the President's $63 billion Global Health Initiative. Prior to her appointment, she was the Senior Vice President for Global Advocacy at Malaria No More, an organization focused on ending deaths from malaria. In 2004, she founded Bio Ventures for Global Health (BVGH), a non-profit working to engage the biopharmaceutical industry to develop medicines for diseases of the developing world. At BVGH, Wendy accelerated global health research and development by building partnerships, identifying market opportunities for industry engagement and advancing the development and implementation of new market incentives including the first Advance Market Commitment and FDA's Priority Review Voucher program. Previously she served as Director of Regulatory Affairs and Bioethics for the Biotechnology Industry Organization (BIO) where she negotiated the third reauthorization of the Prescription Drug User Fee Act (PDUFA) on behalf of the biotech industry and developed the organization's first global health program.
Wendy also has extensive experience in the executive and legislative branches of the US government, including the Office of Management and Budget, where she oversaw FDA regulatory activities, and the U.S. House Committee on Ways and Means. Wendy received a Master of Public Policy from the Kennedy School of Government at Harvard University and a B.A. from Duke University. She serves on the North American Board of Medicines for Malaria Ventures.